The standard of care cohort comprised of patients across 3 global trials acted as a comparator for treatment with cilta-cel in patients with triple-class exposed multiple myeloma.
Further investigation will determine if initial results regarding the use of anakinra as prophylaxis for orvacabtagene autoleucel in multiple myeloma is efficacious enough for use in the real-world setting.
Almost all patients with nonmetastatic castration-resistant prostate cancer treated on the phase 3 ARAMIS trial were able to receive the full planned dose of darolutamide for their disease.
CancerNetwork® sat down with Ola Landgren, MD, PhD, at the 2021 EHA Congress to talk about his presentation on first-line standard of care for multiple myeloma.
Technetium Tc 99m tilmanocept may now be used to enhance identification of lymph nodes in pediatric patients with certain tumors.
CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss results of the CANTATA trial of cabozantinib with or without telaglenastat.
According to data presented at the 2021 ASCO Annual Meeting, patients with crizotinib-refractory ALK-positive non–small cell lung cancer demonstrated long-term response and survival maintenance on brigatinib.
Ola Landgren, MD, PhD, looks at results from the phase 2 CARTITUDE-2 trial of ciltacabtagene autoleucel for patients with multiple myeloma and 1 to 3 prior lines of therapy presented at the 2021 ASCO Annual Meeting.
The CAR T-cell therapy lisocabtagene maraleucel resulted in better efficacy versus standard of care with no new safety signals.
Data from a phase 1b trial of the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma display safety and early efficacy.
Choueiri detailed combination treatments with follow-up data presented at the 2021 ASCO Annual Meeting.
CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about what data has the greatest potential to impact standard treatment of chronic lymphocytic leukemia.
The recommended phase 2 dose of pembrolizumab plus cabozantinib induced a response with a manageable safety profile for patients with mRCC.
Adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses for patients with advanced hepatocellular carcinoma.
Lenvatinib plus pembrolizumab was efficacious for patients with advanced renal cell carcinoma and performed well in subgroup analyses of International Metastatic Renal Cell Carcinoma Database Consortium risk categories and target kidney lesions.
Adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free survival for men with de novo metastatic castration-sensitive prostate cancer.
Subcutaneous Elranatamab had high response rates when given at or above 215 μg/kg.
Reck mentioned the IMpower010 and CheckMate 816 trials investigating treatment options for patients with non-small cell lung cancer.
A post hoc analysis of the CLEAR trial shows that patients may derive an overall survival benefit with lenvatinib plus everolimus versus sunitinib for frontline treatment of RCC, with efficacy ongoing.
Despite failure to reach the primary end point of statistically significant overall survival benefit, TAK-700 plus androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer may be a valid treatment option for some patients.
Larotrectinib’s tumor-agnostic indication for NTRK fusion–positive cancers is further validated by data presented at the 2021 ASCO Annual Meeting.
CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to discuss his thoughts on research he believes has the greatest potential to impact standard of care treatment of bladder cancer.
Data from the MonumentTAL-1 trial detailed the benefits with the recommended phase II dose of talquetamab to treat patients with relapsed/refractory multiple myeloma.
Pimitespib significantly improved progression-free survival while prolonging overall survival compared with placebo to treat patients with advanced gastrointestinal stromal tumor.
Disparities regarding comprehensive genomic profiling came to light during a presentation at the 2021 ASCO Annual Meeting.
Treatment with the off-the-shelf, full-size BCMA X CD3 bi-specific antibody appeared well tolerated with promising efficacy among patients with relapsed/refractory multiple myeloma.
As a bladder-sparing treatment strategy, transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise for patients with muscle-invasive bladder cancer.
The investigational BCMA-directed CAR T-cell therapy sustained durable responses for heavily pretreated patients with relapsed/refractory multiple myeloma.
CAR066, showed a favorable safety profile and promising efficacy in the treatment of adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed prior CD19 CAR T-cell therapy.
Compared to upfront autologous stem cell transplantation for newly diagnosed, transplant-eligible patients with multiple myeloma, carfilzomib consolidation with cyclophosphamide and dexamethasone produced noninferior results.
